Fig 1.
PTENP1 pseudogene sequence (A) and the analyzed region of the pseudogene (B). Red and blue arrows indicate the sites of transcription initiation of the sense (PTENP1) and antisense (PTENP1-AS) transcripts of PTENP1 gene; black arrows indicate the location of primers for MS-PCR; cg12687990—the probe from llumina Infinium Human Methylation 450 (HM450K) bead array, which was used to determine PTENP1 methylations level in samples from TCGA database.
Fig 2.
PTENP1 pseudogene methylation in cell lines (A) and malignant and non-malignant endometrial tissues (B). Cun, unmethylated control (DNA obtained from peripheral blood and treated with sodium bisulfite), Cm, methylated control (DNA obtained from peripheral blood, methylated with SssI methyltransferase, and treated with sodium bisulfite), C0, amplification without a DNA template; un and m–PCR amplification with primers for unmethylated and methylated DNA respectively; M–a molecular weight marker; NE, normal endometrium; EH, endometrial hyperplasia; EP, endometrial polyps; EC, endometrial carcinoma.
Table 1.
Patients and tissue samples.
Table 2.
Significance of differences in the PTENP1 methylation frequency in II and III age groups between various types of endometrial tissue.
Table 3.
PTENP1 methylation analysis in endometrial tissues of women of various age groups.
Fig 3.
The mean relative levels of PTENP1 and PTENP1-AS transcription in NE tissue from women of two age groups (A), the relative levels of PTENP1 (B), PTENP1-AS (C) and PTEN (D) transcripts in human cells, treated with 5-Azacytidine. Group “Young”: 23–30 years (mean age 29±2.07 years, n = 10); group “Old”: 40–43 years (mean age 41.5±1.34 years, n = 10); * p = 0.0313; ns–not significant (p = 0,739); for each cell line untreated cells were used as controls (arbitrary set at 1).
Fig 4.
The Kaplan-Meier survival curve for patients with EC divided into two groups based on the PTENP1 expression level.
The number of patients in each group and the p value (log-rank test) are indicated.
Fig 5.
The Kaplan-Meier survival curve for patients with endometrial cancer (A), sarcoma (B), acute myeloid leukemia (C) and lower grade glioma (D) divided into two groups based on the PTENP1 methylation level. The number of patients in each group and the p-value (log-rank test) are indicated.